Canary Cure’s Game-Changing Obesity Therapy Burns Fat and Protects Muscle

Novel siRNA Therapeutic Demonstrates Significant Fat Loss and Remarkable Lean Body Mass Preservation, and Promises Superior Adherence
New York, NY, January 11, 2025 — Canary Cure Therapeutics, a pioneer in next-generation RNA therapeutics development, today announced breakthrough preclinical results for its lead candidate CCT-217, addressing two critical challenges in current obesity treatments: muscle mass loss and poor medication adherence.
Recent studies have highlighted significant challenges with current GLP-1 receptor agonist therapies, with up to 40% of Type 2 diabetes patients discontinuing treatment within the first year (JAMA, 2024). High discontinuation rates are largely attributed to the burden of weekly injections and side effects affecting up to 85% of patients.

CCT-217 represents a paradigm shift in obesity treatment through its revolutionary approach.

Breakthrough Preclinical Results:
Key Advantages Over Current Therapies:
“CCT-217’s unique dual-mechanism approach represents a fundamental advancement in obesity treatment,” said Raj Reddy, CEO of Canary Cure. “While current therapies often result in significant muscle loss – up to 40% of total weight loss – our technology selectively targets fat tissue while protecting and enhancing lean muscle mass, a critical factor for long-term metabolic health.”
The company’s proprietary technology leverages RNA interference (RNAi) to silence two key genes involved in fat storage and metabolism: CB1R and ZFP423. This dual-targeting approach promotes the conversion of white fat to metabolically active brown fat, increasing energy expenditure without affecting the central nervous system.
Additional Clinical Benefits:
Study report can be found at https://www.biorxiv.org/content/10.1101/2024.12.30.630715v1. The company plans to submit an Investigational New Drug (IND) application by Q3 2025 and begin Phase 1 clinical trials in 2026.
About Canary Cure
Canary Cure is a privately held biotechnology company dedicated to developing innovative RNA interference (RNAi) therapies for the treatment of metabolic diseases. The company’s lead candidate, CCT-217, is a first-in-class dual siRNA therapy targeting CB1r and zfp423 for the treatment of obesity. Canary Cure is committed to advancing RNAi technology to deliver transformative therapies that improve the lives of patients.
Forward-Looking Statements: This press release contains forward-looking statements about Canary Cure’s expectations, plans and prospects. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.

www.canarycure.com

Contact: Anna Wang – Chief Strategy Officer anna@canarycure.com

Share This :